Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for ANGO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2003. Start Trial.
Date Value
May 31, 2026 -0.108M
February 28, 2026 0.621M
November 30, 2025 -0.092M
August 31, 2025 0.143M
May 31, 2025 -5.09M
February 28, 2025 7.147M
November 30, 2024 -1.123M
August 31, 2024 -0.509M
May 31, 2024 -5.00M
February 29, 2024 0.694M
November 30, 2023 -0.352M
August 31, 2023 -59.59M
May 31, 2023 -0.751M
February 28, 2023 0.941M
November 30, 2022 0.148M
August 31, 2022 25.08M
May 31, 2022 0.329M
February 28, 2022 0.966M
November 30, 2021 0.942M
August 31, 2021 5.446M
May 31, 2021 -9.445M
February 28, 2021 -8.022M
November 30, 2020 -0.01M
August 31, 2020 0.491M
May 31, 2020 24.95M
Date Value
February 29, 2020 14.82M
November 30, 2019 0.00
August 31, 2019 -135.01M
May 31, 2019 -7.242M
February 28, 2019 -10.08M
November 30, 2018 53.90M
August 31, 2018 -2.645M
May 31, 2018 -0.861M
February 28, 2018 -0.428M
November 30, 2017 -7.724M
August 31, 2017 -2.538M
May 31, 2017 -6.567M
February 28, 2017 -14.01M
November 30, 2016 -15.60M
August 31, 2016 -1.797M
May 31, 2016 -4.496M
February 29, 2016 -6.797M
November 30, 2015 -10.30M
August 31, 2015 -2.071M
May 31, 2015 -11.11M
February 28, 2015 -2.74M
November 30, 2014 5.772M
August 31, 2014 -2.391M
May 31, 2014 2.64M
February 28, 2014 -5.472M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Boston Scientific Corp. -410.00M
Penumbra, Inc. 9.025M
Abbott Laboratories -3.518B
Alphatec Holdings, Inc. -19.53M
AtriCure, Inc. 3.262M